ALKS Alkermes
- 23.860
- -0.150-0.62%
- 24.600
- +0.740+3.10%
Alkermes News
Stifel Nicolaus Reaffirms Their Hold Rating on Alkermes (ALKS)
HC Wainwright & Co. : The Alkermes (ALKS.US) rating was reaffirmed and adjusted from neutral to neutral, with a target price of $35.00.
Alkermes Analyst Ratings
HC Wainwright & Co. Reiterates Neutral on Alkermes, Maintains $35 Price Target
UBS Adjusts Price Target on Alkermes to $21 From $23, Maintains Sell Rating
Alkermes Buy Rating Affirmed on Strong Commercial Performance and Promising Drug Pipeline
Alkermes Hold Rating Justified by Mixed Financial Performance and Uncertain Pipeline Prospects
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Sagimet Biosciences, Inc. Class A (SGMT) and Alkermes (ALKS)
Maintaining Hold on Alkermes Amidst Modest Q1 Performance and Pipeline Prospects
Analysts Are Bullish on These Healthcare Stocks: Atricure (ATRC), Alkermes (ALKS)
Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Ocular Therapeutix (OCUL)
HC Wainwright & Co. : The Alkermes (ALKS.US) rating was reaffirmed and adjusted from neutral to neutral, with a target price of $35.00.
Alkermes Analyst Ratings
Analysts Conflicted on These Healthcare Names: Enliven Therapeutics (ELVN), Alkermes (ALKS) and Apellis Pharmaceuticals (APLS)
Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS)
Hold Rating on Alkermes Amid Promising ALKS 2680 Data and Regulatory Challenges
Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), DocGo (DCGO) and Alkermes (ALKS)
Balanced Hold Rating for Alkermes Amidst Promising Data and Development Risks
Buy Rating Affirmed for Alkermes on Promising ALKS 2680 Clinical Trial Results and Growth Potential
Alkermes's ALKS-2680 Shows Promising Efficacy in NT2, Enhancing Market Outlook and Supporting a Buy Rating
Analysis
Price Target
No Data
